This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cardinal Health (CAH) Gets FDA Warning for Monoject Syringes
by Zacks Equity Research
The FDA is alerting healthcare providers and facilities against the use of Cardinal Health's (CAH) Monoject syringes with syringe pumps and PCS pumps.
Insulet (PODD) Up 31.5% Since Q3 Earnings: What's Driving It?
by Zacks Equity Research
Insulet (PODD) continues to gain from the strong adoption of Ommipod 5 and market expansion.
Cardinal Health (CAH) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Cardinal Health's (CAH) diversified product portfolio.
Fresenius Medical (FMS) Ups '23 Outlook After Legal Settlement
by Zacks Equity Research
Fresenius Medical (FMS) wins legal dispute against the U.S. government. Both revenues and operating income will benefit from the settlement agreement.
Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.
Patterson Companies (PDCO) Partners With Pearl for AI Services
by Zacks Equity Research
Patterson Companies (PDCO) collaborates with dental AI solution provider, Pearl, to integrate the latter's Second Opinion software solution within its Eaglesoft software to deliver advanced solutions.
Are You Looking for a Top Momentum Pick? Why Integer (ITGR) is a Great Choice
by Zacks Equity Research
Does Integer (ITGR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Nevro's (NVRO) New Data Supports SCS Therapy for NSRBP Treatment
by Zacks Equity Research
Nevro's (NVRO) latest 24-month data demonstrates the benefits of high-frequency 10 kHz SCS therapy for lasting pain relief, enhanced function, quality of life and reduced opioid dependency.
Masimo's (MASI) W1 Medical Watch to Boost Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the latest FDA approval is expected to provide greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily.
Why You Should Add Integer Holdings (ITGR) to Your Portfolio
by Zacks Equity Research
Integer Holdings' (ITGR) research and product development activities and a solid foothold in the broader MedTech space raise optimism about the stock.
What's in the Cards for Medtronic (MDT) in Q2 Earnings?
by Zacks Equity Research
Strength in all four businesses is likely to drive Medtronic's (MDT) fiscal second-quarter performance.
McKesson (MCK) Announces Availability of FDA-Cleared mCRC Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for mCRC.
New Strong Buy Stocks for November 17th
by Zacks Equity Research
DDL, FINW, SCS, PGR and ITGR have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2023.
Best Value Stocks to Buy for November 17th
by Zacks Equity Research
FMN, SCS and ITGR made it to the Zacks Rank #1 (Strong Buy) value stocks list on November 17, 2023.
QIAGEN (QGEN) Expands Sample Technologies Line With New Launch
by Zacks Equity Research
QIAGEN's (QGEN) latest launches will better address the special needs of researchers working with challenging samples, allowing them to work more efficiently.
Catalent (CTLT) Preliminary Q1 Revenues Dampened by Lower Sales
by Zacks Equity Research
Catalent (CTLT) records lower revenues in Biologics segments in its first-quarter fiscal 2024, resulting in overall soft preliminary performance.
ITGR or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ITGR vs. EW: Which Stock Is the Better Value Option?
Alcon (ALC) Q3 Earnings Miss Estimates, Margins Increase
by Zacks Equity Research
Alcon (ALC) Q3 revenues increase year over year, driven by strength in Surgical and Vision Care segments.
Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite
by Zacks Equity Research
Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.
Here's Why You Should Retain Penumbra (PEN) Stock for Now
by Zacks Equity Research
Investors are optimistic about Penumbra (PEN) on strong vascular and neuro businesses growth and upbeat guidance.
Bio-Rad (BIO) Hurt by Macroeconomic Woes, Margin Pressure
by Zacks Equity Research
Bio-Rad's (BIO) margin performance is affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.
Charles River (CRL) to Advance AI Drug Discovery With New Pact
by Zacks Equity Research
Charles River's (CRL) recent partnership will enable the optimization of the discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.
Here's Why You Should Retain CVS Health (CVS) Stock for Now
by Zacks Equity Research
Investors are optimistic about CVS Health's (CVS) strength in Health Care Benefits business arm and stable solvency position.
Quest Diagnostics (DGX) Introduces Mobile Phlebotomy Service
by Zacks Equity Research
Quest Diagnostics (DGX) can offer patients and physicians a seamless connection to Quest Diagnostic's laboratory testing with the launch of Quest Mobile.
Veradigm's (MDRX) New Offering to Enhance Patient Engagement
by Zacks Equity Research
Veradigm's (MDRX) latest solution is likely to offer its clients the right payment option to each individual patient through the right communication channel.